- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05171686
초기 CKD에서 이뇨제 및 부피 과부하 (DOCK)
만성콩팥병에서 이뇨제와 세포외 부피, 나트륨 이뇨 펩티드, 증상 및 심혈관 결과의 변화와의 연관성
Almost 15% of Americans have chronic kidney disease (CKD), with an even higher rate in Veterans due to common risk factors such as high blood pressure and diabetes. People with CKD have a high risk of cardiovascular (CV) diseases, such as heart attacks, heart failure, and strokes. Extra fluid in the body, called volume overload, may lead to CV disease in people with CKD. It is unknown if volume overload develops in the earliest stages of CKD, when treating it with common, inexpensive medicines called diuretics may improve long-term CV outcomes. This study will lay important groundwork to answer this question in Veterans with early CKD by comparing two ways to measure volume overload and studying the change in common symptoms like fatigue and short-term CV function after treatment with diuretic medicines.
연구 개요
상태
상세 설명
The investigators previously showed that brain natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP), measures of ventricular stretch, are associated with death and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) stages 1-3, and the investigators' preliminary pilot results suggest that these natriuretic peptides may correlate with objective measures of excess extracellular volume (ECV) and with symptoms common in CKD. The overarching objective is to determine if initiation of diuretic treatment or increase in dose is associated with changes in BNP and NT-pro-BNP, patient-reported symptom burden, and short-term hemodynamic parameters in patients with CKD stages 1-3 and elevated blood pressure, and whether these changes correlate with changes in ECV. The central hypothesis is that the change in ECV after starting or increasing diuretics in Veterans with stages 1-3 CKD is associated with changes in 1) natriuretic peptides, 2) patient-level factors, and 3) CV physiology.
The investigators will compare the changes in natriuretic peptides, symptoms, and CV parameters with the change in ECV after diuretic initiation or dose increase. The primary aim is to determine if initiation of diuretic treatment or increase in diuretic dose is associated with changes in natriuretic peptides. Secondary aims are to determine the effect of diuretic change on patient-reported symptom burden, and CV physiology.
This clinical trial will include 46 outpatients with CKD stages 1-3 and blood pressure >140/90 mmHg. At the first visit, the investigators will initiate or increase the dose of a thiazide or loop diuretic. Study measures other than echocardiogram will be repeated 4 weeks after the intervention to determine changes in these parameters. ECV will be measured by whole-body multifrequency bioimpedance spectroscopy (BIS), which is a validated, non-invasive, painless measure of ECV. Plasma BNP and NT-pro-BNP will be measured, and patient-reported fatigue, depression, and quality of life will be quantified using validated questionnaires. Hemodynamic parameters include blood pressure, pulse pressure, and total peripheral resistance index (TPRI) and cardiac index measured by Non-Invasive Hemodynamic Monitoring. A transthoracic echocardiogram will measure left ventricular mass index, valvular disease, and diastolic dysfunction.
Variables will be compared within participants between baseline and Visit 2 using paired Wilcoxon Signed Rank tests or paired Student's t tests, depending on variable distributions. Correlations between change in ECV/total body weight and all continuous outcome measures will be analyzed using Spearman or Pearson correlations, applying appropriate transformations. Linear regression analysis will control for clinically relevant variables. The relationship between ECV/total body weight and natriuretic peptides from both visits will be evaluated using a mixed effects model to account for the change in these measures between baseline and Visit 2.
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030-4211
- Michael E. DeBakey VA Medical Center, Houston, TX
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Male or female Veterans age 18 years or older. There will be no upper age limit.
-
The presence of CKD stages 1, 2, or 3, as defined below by Kidney Disease Improving Global Outcomes guidelines, for a period of at least 3 months.
- Stage 1: eGFR 90 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g.
- Stage 2: eGFR 60-89 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g.
- Stage 3: eGFR 30-59 mL/min/1.73 m2.
-
Measured blood pressure either >140 mmHg systolic or >90 mmHg diastolic at the two most recent clinic visits.
-
Able to understand and sign informed consent after the nature of the study has been fully explained.
Exclusion Criteria:
- Unable to understand or provide informed consent.
- Unwilling or unable to participate in the protocol or comply with any of its components.
- CKD stages 4-5, defined as eGFR <30 mL/min/1.73 m2.
- Receiving chronic hemodialysis or peritoneal dialysis.
- Recipient of a kidney transplant.
- Serum potassium <3.5 mEq/L at baseline.
- Known left ventricular ejection fraction <40% on visual estimate based on chart review of available echocardiogram data.
- Known hepatic cirrhosis.
- Major limb amputation.
- Known pregnancy.
- Presence of a pacemaker or defibrillator.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Diuretic augmentation
The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed. |
The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in NT-pro-BNP
기간: 4 weeks
|
Change in NT-pro-BNP from baseline to 4 weeks after intervention |
4 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in BNP
기간: 4 weeks
|
Change in BNP from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in FACIT-F score
기간: 4 weeks
|
Change in fatigue as measured by FACIT-F score from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in QIDS-SR16
기간: 4 weeks
|
Change in depression as measured by the QIDS-SR16 from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in KDQOL
기간: 4 weeks
|
Change in quality of life as measured by the KDQOL from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in total peripheral resistance index
기간: 4 weeks
|
Change in total peripheral resistance index from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in systolic blood pressure
기간: 4 weeks
|
Change in systolic blood pressure from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in diastolic blood pressure
기간: 4 weeks
|
Change in diastolic blood pressure from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in mean arterial pressure
기간: 4 weeks
|
Change in mean arterial pressure from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in pulse pressure
기간: 4 weeks
|
Change in pulse pressure from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in cardiac index
기간: 4 weeks
|
Change in cardiac index from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in extracellular volume normalized/total body weight
기간: 4 weeks
|
Change in extracellular volume normalized to total body weight from baseline to 4 weeks after intervention |
4 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Lucile P Gregg, MD MS, Michael E. DeBakey VA Medical Center, Houston, TX
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 혈관 질환
- 심혈관 질환
- 병리학적 과정
- 남성 비뇨 생식기 질환
- 신장 질환
- 비뇨기과 질환
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 만성 질환
- 질병 속성
- 신부전
- 병리학적 상태, 징후 및 증상
- 고혈압
- 신부전, 만성
- 황 화합물
- 유기 화학 물질
- 피리딘
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 탄화수소, 순환
- 카르 복실 산
- 탄화수소, 방향족
- 아미드
- 아닐린 화합물
- 아민
- 벤젠 유도체
- 프탈리 미드
- 산, 카르 보 사이 클릭
- Isoindoles
- 벤젠 설포 아미드
- 설폰 아미드
- 설파 닐라 미드
- 설폰
- 아미노벤조테스
- 벤조테스
- 케톤
- 벤조 페논
- 클로로 티아 지드
- 벤조디아디아진
- 티아 지드
- Imides
- 메타 아미노 벤조이트
- 토르세마이드
- 푸로세마이드
- 부메타니드
- 히드로클로로티아지드
- 클로르탈리돈
기타 연구 ID 번호
- NEPH-001-21S
- 1IK2CX002368-01A1 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .